NMRA (Sri Lanka)

The Sri Lanka National Medicines Regulatory Authority (NMRA — ජාතික ඖෂධ නියාමන අධිකාරිය / தேசிய மருந்து ஒழுங்குபடுத்தும் அதிகாரசபை) operating as autonomous statutory authority under the Ministry of Health is the Democratic Socialist Republic of Sri Lanka's national regulatory authority for human + veterinary medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + traditional + complementary medicines (Ayurveda + Siddha + Unani + Homeopathy + Indigenous Sinhala medicine) + pharmacy practice + controlled substances + clinical trials. The NMRA operates under the National Medicines Regulatory Authority Act No. 5 of 2015 + Poisons, Opium and Dangerous Drugs Ordinance + Pharmacists Act + Indigenous Medicine Act + NMRA Board Decisions + NMRA Director General Orders + NMRA Office Circulars + NMRA Guidelines.

NMRA organisational structure includes:

• Minister of Health — political head; appointed by the President.
• Secretary, Ministry of Health — administrative head.
• NMRA Board — chaired by Chairperson appointed by Minister; substantial governance role.
• Director General, NMRA — NMRA chief executive.
• Deputy Director Generals (Drug Evaluation, Medical Devices, Quality Control, Pharmacovigilance) — operational deputies.
• Drug Evaluation Committee + Medical Devices Evaluation Committee + Cosmetics Evaluation Committee — substantive evaluation committees.
• Drug Registration Division — drug + biological + vaccine + generic registration.
• Pharmaceutical Inspection Division — GMP + GDP + GPP inspections of Sri Lankan + foreign manufacturing facilities.
• Pharmacy Practice + Licensing Division — pharmacy + pharmaceutical-establishment licensing in coordination with Sri Lanka Pharmaceutical Society.
• Medical Devices + Cosmetics Division — medical-device + IVD + cosmetic registration.
• Controlled Substances + Narcotics Division — narcotics + psychotropics framework coordination with Police Narcotic Bureau + Sri Lanka Customs.
• National Pharmacovigilance Centre — WHO PIDM affiliated national pharmacovigilance hub.
• Clinical Trials + Bioequivalence Division — CTA + Ethics Committee + IRB coordination.
• National Drug Quality Assurance Laboratory (NDQAL) Colombo — pharmaceutical + biological + diagnostic testing capacity pursuing ISO/IEC 17025 + WHO PQ-Lab status.
• International Affairs Division — WHO + SAARC + Commonwealth + bilateral coordination.
• 9 Provincial Director of Health Services coordination + 25 District Director of Health Services coordination — operational provincial structure.
• Sri Lanka Medical Council (SLMC) — statutory body regulating physician + dental licensing.
• Sri Lanka Pharmaceutical Society — pharmacist licensing professional body.
• Department of Ayurveda — indigenous Ayurveda + Siddha + Unani + Homeopathy regulator coordinated with NMRA for traditional medicine framework.

Sri Lanka's distinctive Indian-Ocean regulatory hub + macroeconomic-crisis operational context: Sri Lanka operates within South Asia's Indian-Ocean regulatory hub with substantial post-2009 conflict-recovery operational context + substantial post-2022 macroeconomic-crisis operational context. The 2022 sovereign-debt default + currency-crisis triggered substantial IMF Extended Fund Facility (EFF) programme conditionality affecting pharmaceutical procurement + State Pharmaceuticals Corporation (SPC) + State Pharmaceuticals Manufacturing Corporation (SPMC) substantial public-sector pharmaceutical-procurement dominant role + substantial currency-crisis-driven medicine-shortage operational reality. Sri Lanka has ~40+ Sri Lankan-domestic manufacturers including State Pharmaceuticals Manufacturing Corporation (SPMC) + Cyrix Healthcare + George Steuart Health + Astron Limited + Hemas Pharmaceuticals + Stallion Pharmaceuticals + Interpharm + Lina Manufacturing + SHG Pharmaceuticals but substantial Indian + Pakistani + Bangladeshi + Chinese pharmaceutical-import dependency. State Pharmaceuticals Corporation (SPC) operates as Sri Lanka's dominant public-sector pharmaceutical procurer reaching ~USD 400+ million annual procurement including substantial WHO PQ + India + Pakistan + Bangladesh + China + Indonesia + Egypt pharmaceutical-procurement.

NMRA is distinct from + complementary to: the Sri Lanka Medical Council (SLMC — physician + dental licensing); the Sri Lanka Pharmaceutical Society (pharmacist licensing professional body); the Department of Ayurveda (indigenous Ayurveda + Siddha + Unani + Homeopathy regulator coordinated with NMRA); State Pharmaceuticals Corporation (SPC — substantial public-sector pharmaceutical procurement); State Pharmaceuticals Manufacturing Corporation (SPMC — substantial domestic manufacturing); Police Narcotic Bureau (narcotics enforcement); Sri Lanka Customs (import-export control); 9 Provincial + 25 District Director of Health Services (provincial healthcare-delivery + drug inspection coordination); academic-medical-centre clinical-research hubs (University of Colombo Faculty of Medicine + University of Peradeniya + University of Kelaniya + University of Sri Jayewardenepura + University of Ruhuna + University of Jaffna + Postgraduate Institute of Medicine). Sri Lanka's pharmaceutical environment is uniquely characterised by: substantial post-2022 macroeconomic-crisis + IMF Extended Fund Facility programme operational context; substantial State Pharmaceuticals Corporation (SPC) public-sector pharmaceutical-procurement dominant role; substantial Indian + Pakistani + Bangladeshi + Chinese pharmaceutical-import dependency; substantial Commonwealth + SAARC + Indian-Ocean regional pharmaceutical regulatory cooperation; distinctive indigenous Ayurveda + Siddha + Unani + Homeopathy + Sinhala-traditional medicine framework; Sinhala + Tamil + English overlay labelling; substantial Climate Zone IVb tropical-monsoon + IVa mid-hill-country + IVc up-country stability requirements.

NMRA is a WHO PIDM Member + WHO SEARO observer + SAARC Member State + Commonwealth Member State + WHO PQ programme participant + ICH Observer + maintains substantial bilateral cooperation with Indian CDSCO + Pakistani DRAP + Bangladeshi DGDA + Nepalese DDA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH + Chinese NMPA + UK MHRA + EU EMA + US FDA + Japanese PMDA + Korean MFDS + Australian TGA + Singapore HSA + Malaysian NPRA + GCC GHC.

Sri Lankan pharmaceutical regulation operates under a layered framework of Acts + Ordinances + NMRA Board Decisions + NMRA Director General Orders + NMRA Office Circulars + NMRA Guidelines — substantively incorporating WHO + ICH + PIC/S GMP + EU GMP + WHO TRS Annex elements:

• National Medicines Regulatory Authority Act No. 5 of 2015 — foundational autonomous-regulator law replacing the Cosmetics, Devices and Drugs Act No. 27 of 1980.
• Poisons, Opium and Dangerous Drugs Ordinance — narcotics + psychotropics framework coordinated with Police Narcotic Bureau.
• Pharmacists Act — pharmacist licensure framework.
• Indigenous Medicine Act — distinctive Sri Lankan Ayurveda + Siddha + Unani + Homeopathy + Sinhala-indigenous medicine framework coordinated with Department of Ayurveda.
• Sri Lanka Medical Council Act — physician + dental licensing framework.
• Sri Lanka National Drug Policy — strategic pharmaceutical policy framework + Essential Drugs List + National Formulary.
• NMRA Drug Registration Guidelines — substantive drug registration framework.
• NMRA Medical Device Guidelines — substantively incorporating WHO + IMDRF + EU MDR + IVDR elements.
• NMRA Cosmetics Guidelines — substantively incorporating EU Cosmetics Regulation elements.
• NMRA GMP Guide — substantively aligned with WHO TRS 986 Annex 2 + PIC/S GMP + EU GMP elements.
• NMRA GDP Guide — substantively aligned with WHO GDP + EU GDP elements.
• NMRA GCP Guide — substantively aligned with ICH E6(R2) + WHO GCP guidance.
• NMRA GVP Guide — substantively aligned with WHO PV guidance + ICH E2 + EU GVP elements.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + International Pharmacopoeia + Indian Pharmacopoeia + Sri Lankan Ayurvedic Pharmacopoeia.
• Sri Lanka National Essential Medicines List + National Formulary — substantively aligned with WHO Essential Medicines List.
• Public-Sector Procurement Framework — substantial State Pharmaceuticals Corporation (SPC) public-sector pharmaceutical-procurement dominant framework reaching ~USD 400+ million annual procurement; substantial WHO PQ + India + Pakistan + Bangladesh + China + Indonesia + Egypt pharmaceutical-procurement.
• IMF Extended Fund Facility Operational Framework — substantial post-2022 macroeconomic-crisis + IMF Extended Fund Facility programme conditionality affecting pharmaceutical procurement + currency-crisis-driven medicine-shortage operational reality.
• Variations + Registration Renewal framework.
• Counterfeit-Medicine Surveillance Framework — substantial Police Narcotic Bureau + NMRA + Sri Lanka Customs coordination for counterfeit + substandard medicine surveillance.

NMRA operates the National Drug Quality Assurance Laboratory (NDQAL) Colombo — substantial pharmaceutical + biological + diagnostic testing capacity pursuing ISO/IEC 17025 + WHO PQ-Lab status via WHO + bilateral-donor capacity expansion. The NMRA Pharmaceutical Inspection Division conducts substantial GMP + GDP + GPP inspections of ~40+ Sri Lankan-domestic manufacturing facilities + foreign manufacturing facilities for imported drug registration.

• ISO/IEC 17025 — NDQAL pursuing ISO/IEC 17025 accreditation via WHO + bilateral-donor capacity expansion.
• WHO PQ-Lab — NDQAL pursuing WHO PQ-Lab status via WHO + bilateral-donor capacity expansion.
• Vaccine cold-chain QC — substantial cold-chain capacity for Sri Lanka Expanded Programme on Immunization (EPI) via WHO + UNICEF + Gavi-supported infrastructure.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + substantial post-market surveillance + targeted enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Counterfeit-medicine forensics — substantial forensic analytical support for NMRA + Police Narcotic Bureau + Sri Lanka Customs + WHO Global Surveillance & Monitoring System contributions.
• SPC procurement QC support — NDQAL supports substantial SPC public-sector pharmaceutical-procurement quality assurance reaching ~USD 400+ million annual procurement.
• GMP Inspectorate — substantial NMRA Pharmaceutical Inspection Division capability for Sri Lankan-domestic manufacturing facility GMP inspections including ~40+ manufacturers + foreign manufacturing facility inspections for imported drug registration.
• Sri Lankan domestic manufacturer support — supports substantial Sri Lankan-domestic pharmaceutical-manufacturing industry including ~40+ manufacturers notably State Pharmaceuticals Manufacturing Corporation (SPMC) + Cyrix Healthcare + George Steuart Health + Astron Limited + Hemas Pharmaceuticals + Stallion Pharmaceuticals + Interpharm + Lina Manufacturing + SHG Pharmaceuticals.

NMRA medical-device + IVD regulation operates under NMRA Medical Device Guidelines substantively incorporating WHO + IMDRF + EU MDR + IVDR + GHTF elements. Sri Lanka has minimal domestic medical-device-manufacturing capacity with substantial Indian + Chinese + Pakistani + European + US + Japanese medical-device-import dependency including substantial post-2022 macroeconomic-crisis import-financing challenges.

• Risk-based Classification — substantively aligned with WHO + IMDRF + EU MDR + IVDR + GHTF model.
• Sri Lankan Authorised Representative — Sri Lanka-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + NMRA regulatory interface.
• ISO 13485:2016 — recognised by NMRA as QMS evidence framework.
• Reliance pathways — NMRA accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + WHO PQ + Indian CDSCO + Pakistani DRAP + Bangladeshi DGDA approval evidence as supporting evidence.
• Post-market vigilance — NMRA operates medical-device adverse-event reporting; reporting timelines substantively aligned with WHO + IMDRF Adverse Event Reporting Codes.
• IVD Reactivigilance — NMRA operates IVD reactivigilance reflecting Sri Lanka's substantial clinical-laboratory infrastructure.
• Cosmetic Notification — cosmetics require NMRA Cosmetic Notification + Sinhala/Tamil/English labelling; INCI-aligned ingredient listing + safety substantiation.
• Indigenous + Traditional Medicines — distinctive Sri Lankan indigenous Ayurveda + Siddha + Unani + Homeopathy + Sinhala-traditional medicine framework coordinated with Department of Ayurveda recognising substantial Sri Lankan Ayurvedic Pharmacopoeia + ~3,000-year indigenous Sinhala medical heritage including substantial Hela Wedakama + Deshiya Chikitsa (indigenous Sinhala medicine) tradition.

NMRA operates the National Pharmacovigilance Centre coordinated by NMRA's Pharmacovigilance Division. Sri Lanka is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The National Pharmacovigilance Centre coordinates with 9 Provincial + 25 District Director of Health Services + healthcare-delivery facilities + Marketing Authorisation Holders. Sri Lankan pharmacovigilance is uniquely shaped by substantial post-2022 macroeconomic-crisis operational context + substantial SPC public-sector pharmaceutical-procurement dominant role + substantial vaccine surveillance commitments (Sri Lanka Expanded Programme on Immunization + UNICEF + Gavi-supported campaigns) + substantial counterfeit + substandard medicine quality-risk monitoring.

• National Pharmacovigilance Centre — coordinated by NMRA Pharmacovigilance Division.
• WHO PIDM Member — Sri Lanka contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Sri Lanka PV Network — coordinated national network with effector centres in 9 Provincial + 25 District Director of Health Services + healthcare-delivery facilities + Marketing Authorisation Holders.
• ADR Reporting — NMRA operates ADR reporting via National Pharmacovigilance Centre; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — NMRA accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with ICH E2 + WHO PV guidance.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
• Risk Management Plans (RMP) — NMRA requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — National Pharmacovigilance Centre operates active-surveillance programmes for COVID-19 vaccines + childhood immunisation + high-risk products.
• AEFI Surveillance — Sri Lankan vaccine adverse-event surveillance aligned with WHO methodology; substantial to Sri Lanka Expanded Programme on Immunization + UNICEF + Gavi-supported immunisation campaigns.
• Matériovigilance + Cosmétovigilance — NMRA operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — substantial role given Sri Lanka's substantial pharmaceutical supply-chain complexity + cross-border Indian + Pakistani + Bangladeshi + Chinese pharmaceutical-trade quality risks + substantial post-2022 macroeconomic-crisis import-financing operational complexity.
• SPC Procurement Quality Surveillance — substantial SPC public-sector pharmaceutical-procurement quality surveillance support reaching ~USD 400+ million annual procurement + substantial WHO Global Surveillance & Monitoring System contributions.

• WHO PIDM Member — Sri Lanka contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• WHO PQ Programme Participant + Substantial WHO PQ-Approved-Product Reliance — substantial WHO PQ-procured medicines + vaccines central to Sri Lankan public-sector pharmaceutical procurement via SPC.
• WHO SEARO observer — substantial WHO South-East Asia Regional Office cooperation reflecting Sri Lanka's South Asian regional position.
• SAARC Member State — South Asian Association for Regional Cooperation (8 Member States — Afghanistan + Bangladesh + Bhutan + India + Maldives + Nepal + Pakistan + Sri Lanka); substantial SAARC pharmaceutical regulatory cooperation.
• Commonwealth Member State — substantial Commonwealth pharmaceutical regulatory cooperation reflecting substantial historical UK + Australian + Canadian + South African + Indian + Pakistani + Bangladeshi + Singapore + Malaysian Commonwealth heritage + pharmaceutical-trade.
• ICH Observer — substantial ICH guideline implementation in Sri Lankan regulatory practice.
• Indian CDSCO Bilateral — substantial South Asian + SAARC peer + cross-border pharmaceutical-trade + substantial Indian pharmaceutical-import dependency.
• Pakistani DRAP Bilateral — SAARC peer + halal-pharmaceutical cooperation + substantial Pakistani pharmaceutical-import.
• Bangladeshi DGDA Bilateral — SAARC peer + substantial Bangladeshi pharmaceutical-import + Bangladesh SAARC Secretariat host country cooperation.
• Nepalese DDA + Bhutanese DRA + Maldivian MFDA Bilateral — substantial SAARC peer cooperation.
• Afghanistan MoPH Bilateral — SAARC peer cooperation.
• Chinese NMPA Bilateral — Belt and Road operational engagement + substantial Chinese pharmaceutical-import + medical-device-import dependency + Hambantota Port + Colombo Port City strategic-investment context.
• UK MHRA Bilateral — substantial historical Commonwealth + Sri Lanka-UK pharmaceutical heritage.
• EU EMA + US FDA + Japanese PMDA + Korean MFDS + Australian TGA + Singapore HSA + Malaysian NPRA Bilateral — substantial international + Commonwealth + Indian-Ocean regional cooperation.
• GCC GHC Bilateral — substantial Sri Lankan-diaspora + GCC pharmaceutical export-market cooperation.
• Indian Ocean Commission (IOC) — substantial Indian Ocean Commission regional cooperation reflecting Sri Lanka's Indian-Ocean regional position.
• IMF Extended Fund Facility Programme — substantial post-2022 macroeconomic-crisis + IMF Extended Fund Facility programme conditionality cooperation framework affecting pharmaceutical procurement.
• World Bank + Asian Development Bank — substantial World Bank + Asian Development Bank cooperation on Sri Lankan healthcare-system + pharmaceutical-procurement support.

• Post-2022 macroeconomic-crisis + IMF EFF programme operational context under-planned — most operationally significant feature of Sri Lankan pharmaceutical market access; substantial post-2022 macroeconomic-crisis + IMF Extended Fund Facility programme conditionality + substantial currency-crisis-driven medicine-shortage + import-financing operational complexity frequently under-planned by foreign manufacturers.
• SPC public-sector procurement pathway under-planned — substantial State Pharmaceuticals Corporation (SPC) public-sector pharmaceutical-procurement dominant role reaching ~USD 400+ million annual procurement frequently under-planned by foreign manufacturers.
• NMRA Act No. 5 of 2015 autonomous-regulator framework under-planned — substantial NMRA Act No. 5 of 2015 autonomous-regulator framework + NMRA Board governance role frequently under-planned by foreign manufacturers more familiar with legacy Cosmetics, Devices and Drugs Act No. 27 of 1980 framework.
• Sri Lankan Authorised Representative not properly designated — application rejected at NMRA intake or post-approval compliance failure; Sri Lankan Authorised Representative must be Sri Lanka-resident legal entity with appropriate licensure.
• Sinhala + Tamil + English labelling deficiencies — Sinhala + Tamil + English required; many applicants provide insufficient Sinhala + Tamil language patient leaflet content.
• NMRA GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Sri Lankan-specific NMRA GMP clarifications.
• Sri Lankan climate-zone stability data missing — Sri Lanka spans Climate Zone IVb tropical-monsoon + IVa mid-hill-country + IVc up-country; requires substantial zonal-specific stability data including monsoon-humidity considerations.
• WHO PQ programme reliance under-utilised — substantial WHO PQ-approved-product reliance pathway substantially central to SPC public-sector procurement frequently under-utilised.
• SRA reliance under-utilised — substantial EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS reliance pathway frequently under-utilised.
• SAARC peer reliance under-utilised — substantial Indian CDSCO + Pakistani DRAP + Bangladeshi DGDA peer reliance pathway reflecting substantial Indian/Pakistani/Bangladeshi pharmaceutical-import dependency frequently under-utilised.
• SPMC domestic-manufacturing pathway under-leveraged — substantial State Pharmaceuticals Manufacturing Corporation (SPMC) domestic-manufacturing pathway for essential-medicines including substantial WHO PQ + bilateral-donor technology-transfer + joint-venture opportunities frequently under-leveraged.
• Bioequivalence centres + biowaiver — NMRA BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• Counterfeit + substandard medicine quality risks under-monitored — Sri Lanka's substantial pharmaceutical supply-chain complexity + cross-border Indian + Pakistani + Bangladeshi + Chinese pharmaceutical-trade + substantial post-2022 macroeconomic-crisis import-financing operational complexity create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance.
• Substantial Sri Lankan-domestic manufacturer joint-venture not leveraged — substantial Sri Lankan-domestic pharmaceutical-manufacturing capacity including ~40+ manufacturers substantially under-leveraged for foreign-manufacturer technology-transfer + joint-venture opportunities.
• Substantial Sri Lankan academic-medical-centre clinical-research capacity not leveraged — substantial University of Colombo + University of Peradeniya + University of Kelaniya + University of Sri Jayewardenepura + University of Ruhuna + University of Jaffna + Postgraduate Institute of Medicine + 22-million-population clinical-research capacity substantially under-leveraged.
• Department of Ayurveda + indigenous medicine framework not anticipated — distinctive Sri Lankan indigenous Ayurveda + Siddha + Unani + Homeopathy + Sinhala-traditional Hela Wedakama medicine framework coordinated with Department of Ayurveda frequently under-anticipated by foreign manufacturers.
• Variations strategy not planned — variations procedure with Sri Lankan-specific timelines + fee structure + macroeconomic-crisis operational delays.
• Registration renewal timing missed — registration renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.
• Commonwealth + Indian-Ocean regional bridging not leveraged — substantial Commonwealth + Indian-Ocean regional regulatory cooperation + harmonisation opportunities substantially under-leveraged.

V5 Ultimate provides the operational infrastructure Sri Lankan + foreign-supplier sites need for the National Medicines Regulatory Authority Act No. 5 of 2015 + NMRA Drug Registration + NMRA GMP + NMRA Medical Device Guidelines + NMRA Cosmetics Guidelines + WHO PQ programme participation + SPC public-sector procurement coordination + SPMC domestic-manufacturing technology-transfer + SAARC + Commonwealth + Indian-Ocean regional cooperation + National Pharmacovigilance Centre + substantial post-2022 macroeconomic-crisis + IMF Extended Fund Facility programme operational context compliance support.

• NMRA GMP control framework — WHO TRS 986 Annex 2 + PIC/S + EU GMP elements-aligned controls with ALCOA+ data-integrity + Sri Lankan-specific clarifications + Climate Zone IVb tropical-monsoon + IVa mid-hill-country + IVc up-country stability monitoring.
• NMRA registration dossier packaging — Sri Lankan CTD-aligned dossier structure with Sri Lankan Module 1 specifics + Module 3 stability + Sinhala/Tamil/English patient leaflet + Sri Lankan Authorised Representative declarations + NMRA Act No. 5 of 2015 framework + substantial EU Module reuse.
• Post-2022 macroeconomic-crisis + IMF EFF programme workflow — most operationally significant feature; substantial post-2022 macroeconomic-crisis + IMF Extended Fund Facility programme conditionality + substantial currency-crisis-driven medicine-shortage + import-financing operational complexity packaging.
• SPC public-sector procurement workflow — substantial State Pharmaceuticals Corporation (SPC) public-sector pharmaceutical-procurement dominant pathway packaging reaching ~USD 400+ million annual procurement; substantial WHO PQ + India + Pakistan + Bangladesh + China + Indonesia + Egypt pharmaceutical-procurement coordination.
• SPMC domestic-manufacturing workflow — substantial State Pharmaceuticals Manufacturing Corporation (SPMC) domestic-manufacturing pathway for essential-medicines packaging including substantial WHO PQ + bilateral-donor technology-transfer + joint-venture opportunities support.
• WHO PQ programme reliance workflow — substantial WHO PQ-approved-product reliance pathway packaging — central to SPC public-sector procurement.
• SRA reliance workflow — NMRA-EMA + NMRA-FDA + NMRA-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging.
• SAARC peer reliance workflow (Indian CDSCO / Pakistani DRAP / Bangladeshi DGDA / Nepalese DDA / Bhutanese DRA / Maldivian MFDA / Afghanistan MoPH) — substantial SAARC peer reliance packaging reflecting substantial Indian/Pakistani/Bangladeshi pharmaceutical-import dependency.
• Sri Lankan Authorised Representative workflow — foreign-manufacturer Sri Lankan Authorised Representative designation + role-management + Sri Lanka-specific post-market surveillance.
• Sri Lankan clinical-trial workflow — NMRA CTA + University of Colombo + University of Peradeniya + University of Kelaniya + University of Sri Jayewardenepura + University of Ruhuna + University of Jaffna + Postgraduate Institute of Medicine Ethics Committee + IRB coordination + Sri Lankan SUSAR reporting via National Pharmacovigilance Centre.
• National Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Sri Lankan ICSR + Sri Lanka PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + indigenous-medicine workflow — NMRA frameworks dossier packaging + risk-based classification + ISO 13485 + Sri Lankan Authorised Representative + post-market vigilance + distinctive Sri Lankan indigenous Ayurveda + Siddha + Unani + Homeopathy + Sinhala-traditional Hela Wedakama medicine framework coordinated with Department of Ayurveda.
• Counterfeit + substandard medicine surveillance workflow — Sri Lanka's substantial pharmaceutical supply-chain complexity + cross-border Indian + Pakistani + Bangladeshi + Chinese pharmaceutical-trade + post-2022 macroeconomic-crisis import-financing quality-risk monitoring + WHO Global Surveillance & Monitoring System integration.
• SAARC + Commonwealth + Indian-Ocean regional bridging — for companies operating across SAARC + Commonwealth + Indian-Ocean regional jurisdictions, V5 surfaces NMRA + India CDSCO + Pakistan DRAP + Bangladesh DGDA + Nepalese DDA + Bhutanese DRA + Maldivian MFDA + Afghanistan MoPH + UK MHRA + Australian TGA + Singapore HSA + Malaysian NPRA + GCC GHC harmonised dossier-element reuse alongside national-specific extensions + macroeconomic-crisis operational context compliance.